Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
2.99 (USD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Black Diamond Therapeutics, Inc. |
Symbool | BDTX |
Munteenheid | USD |
Prijs | 2.99 |
Beurswaarde | 168,949,651 |
Dividendpercentage | 0% |
52-weken bereik | 1.62 - 7.66 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mark A. Velleca M.D., Ph.D. |
Website | https://www.blackdiamondtherapeutics.com |
An error occurred while fetching data.
Over Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)